Company Profile
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The company’s lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy.
Latest Quarterly Earnings
Press Releases
Nov 09, 2022
Oct 31, 2022
Oct 25, 2022
View All - News
Events
May 25, 2022 at 10:45 AM EDT
Mar 17, 2022 at 10:15 AM EDT
Mar 7, 2022 at 9:10 AM EST
View All - Events
Presentations